Status:
COMPLETED
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Neuroblastoma
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giv...
Detailed Description
OBJECTIVES: Primary * Determine the response rate in pediatric patients with relapsed neuroblastoma (NB) treated with irinotecan hydrochloride and temozolomide. * Determine the toxicities associated...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed neuroblastoma AND/OR demonstration of tumor cells in the bone marrow with increased urinary catecholamines at initial diagnosis
- Patients with elevated catecholamines only are not eligible
- Meets 1 of the following criteria:
- Recurrent disease following aggressive, multidrug, frontline chemotherapy, defined as chemotherapy given with ≥ 2 agents, including an alkylating agent and a platinum-containing compound
- Resistant/refractory disease during aggressive, multidrug, frontline chemotherapy
- Must meet 1 of the following criteria for documentation of disease:
- Unidimensionally measurable tumor ≥ 20 mm by MRI (Magnetic Resonance Imaging), CT scan (Computed Tomography), or x-ray OR ≥ 10 mm by spiral CT scan within 4 weeks prior to study entry
- Patients with residual stable tumor upon completion of frontline therapy must undergo biopsy to document presence of a viable neuroblastoma
- If the measurable target lesion was previously radiated, a biopsy must be performed ≥ 4 weeks after radiation was completed AND the biopsy must demonstrate viable neuroblastoma
- MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical) with positive uptake at ≥ 1 site within 4 weeks prior to study entry
- Patients with residual stable MIBG-positive lesions upon completion of frontline therapy must undergo biopsy to document presence of viable neuroblastoma
- If the patient has only 1 MIBG-positive lesion, and that lesion was previously radiated, a biopsy must be performed ≥ 4 weeks after radiation was completed AND the biopsy must demonstrate viable neuroblastoma
- Bone marrow with tumor cells on routine morphology (not by neuron-specific enolase staining only) of bilateral aspirate and/or biopsy on 1 bone marrow sample within 2 weeks prior to study entry
- No extensive marrow disease
- No myelodysplastic syndrome
- PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 50-100% (for patients \> 16 years of age) OR Lansky PS 50-100% (for patients ≤ 16 years of age)
- Life expectancy ≥ 8 weeks
- Absolute neutrophil count ≥ 750/mm\^3
- Platelet count ≥ 75,000/mm\^3 (transfusion independent)
- Hemoglobin ≥ 8.5 mg/dL (transfusion allowed)
- Creatinine adjusted according to age as follows:
- No greater than 0.4 mg/dL (≤ 5 months)
- No greater than 0.5 mg/dL (6 months -11 months)
- No greater than 0.6 mg/dL (1 year-23 months)
- No greater than 0.8 mg/dL (2 years-5 years)
- No greater than 1.0 mg/dL (6 years-9 years)
- No greater than 1.2 mg/dL (10 years-12 years)
- No greater than 1.4 mg/dL (13 years and over \[female\])
- No greater than 1.5 mg/dL (13 years to 15 years \[male\])
- No greater than 1.7 mg/dL (16 years and over \[male\]) OR
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- ALT \< 2.5 times ULN for age
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Seizure disorder allowed provided seizures are well controlled on non-EIAC medication
- No active diarrhea or uncontrolled infection
- No other malignancy, including secondary malignancy
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior front-line therapy (e.g., surgery, chemotherapy, immunotherapy, radiotherapy, or retinoids) allowed
- Recovered from prior therapy
- More than 4 weeks since prior radiation therapy to the site of any lesion that will be identified as a target lesion to measure tumor response
- At least 2 weeks since prior myelosuppressive therapy (4 weeks for nitrosourea)
- At least 1 week since prior therapy with an antineoplastic biologic agent or retinoid
- At least 1 week since prior growth factors
- At least 1 week since prior and no other concurrent anticancer agents
- At least 1 week since prior and no concurrent enzyme-inducing anticonvulsants (EIAC), including phenytoin, phenobarbital, valproic acid, or carbamazepine
- Concurrent gabapentin or levetiracetam allowed
- Concurrent palliative radiation therapy to sites not used to measure tumor response allowed
- No prior allogeneic stem cell transplantation (SCT)
- Prior autologous SCT allowed
- No prior second-line chemotherapy for relapsed or refractory disease
- No concurrent immunomodulating agents
- Concurrent steroids for transfusion/infusion reactions or for treatment of edema associated with CNS lesions allowed
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00311584
Start Date
April 1 2006
End Date
December 1 2013
Last Update
September 30 2014
Active Locations (128)
Enter a location and click search to find clinical trials sorted by distance.
1
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama, United States, 35294
2
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States, 85724-5024
3
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
4
Southern California Permanente Medical Group
Downey, California, United States, 90242-2814